MARKET NEWS

Catalent Expands Primary Packaging Capabilities at its Clinical Supply Facility in Japan
BioCorRx Announces First Subject Dosed in Phase 1 Clinical Trial of Implantable Naltrexone Pellet
Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Peripheral NLRP3 Inhibitor
SciSparc Successfully Completed Development of its Proprietary Drug Candidate for Upcoming Phase 2b Study in Tourette Syndrome
Ocuphire Granted New US Patent for Late-Stage Oral Drug Candidate 
BriaCell Enters Research Agreement to Identify Novel Targets for Cancer Treatment

  FEATURED EDITORIAL

  COMPANY PROFILE

Evonik Health Care is a global innovation hub for the world’s leading life science companies. We support customers along the entire product cycle from early development to commercial manufacturing. Our system solutions are backed by the scientific excellence of our interdisciplinary and diverse teams. As an integrated CDMO, Evonik Health Care has been a leader for advanced drug delivery for many decades. It is also one of the world’s largest contract manufacturers of high potency APIs (HPAPIs) and active pharmaceutical ingredients (APIs) that require complex chemistry and multiple-step syntheses. Click here for more.

Video Spotlight: MilliporeSigma – Emprove® Excipients for Full Supply Chain Transparency

  EXCLUSIVE ONLINE CONTENT

Cara Therapeutics Announces Positive Topline Results From Phase 2 Trial of Oral Difelikefalin 

Cara Therapeutics Announces Positive Topline Results From Phase 2 Trial of Oral Difelikefalin 

Cara Therapeutics, Inc. recently announced positive topline results from its Phase 2 proof-of-concept clinical trial (KOMFORT) evaluating oral difelikefalin for the treatment of moderate-to-severe pruritus in….

US Government to Support Expansion of Croda Lipid Systems Capability

US Government to Support Expansion of Croda Lipid Systems Capability

Croda International Plc recently announced it has entered into a cooperative agreement with the US government in which the government will provide up to $75 million to expand the….

Neurona Therapeutics Announces Initial Subject Dosed in First Clinical Trial of Regenerative Human Cell Therapy in Adults with Drug-Resistant Focal Epilepsy

Neurona Therapeutics Announces Initial Subject Dosed in First Clinical Trial of Regenerative Human Cell Therapy in Adults with Drug-Resistant Focal Epilepsy

Neurona Therapeutics recently announced the first patient dosed in a Phase 1/2 clinical trial of its lead program, NRTX-1001, in a first-in-human epilepsy study…..

AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease

AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease

AN2 Therapeutics, Inc. recently announced it has screened its first patient in its pivotal Phase 2/3 clinical trial evaluating once-daily, oral epetraborole for treatment-refractory Mycobacterium avium complex…..

  WHITEPAPERS & WEBINARS

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

In this webinar, experts will provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon. In addition, experts will also provide insights into how softgel capsules, formed by the combination of both pectin and gelatin, are used in OptiGel® DR, a new delayed release delivery technology for pharmaceutical applications.

WEBINAR - Understanding Patch Composition for Effective Transdermal Delivery

WEBINAR - Understanding Patch Composition for Effective Transdermal Delivery

As the advantages of transdermal drug delivery grow, the global market for transdermal patches also is growing. Join DuPont™ Liveo™ Healthcare Solutions and Gattefossé Pharmaceuticals for a complimentary one-hour webinar to explore the current….

  WHITEPAPERS & WEBINARS

WHITEPAPER - The Viscosity Reduction Platform: Viscosity-Reducing Excipients for Protein Formulation

WHITEPAPER - The Viscosity Reduction Platform: Viscosity-Reducing Excipients for Protein Formulation

This white paper evaluates the viscosity-reducing capacities of excipients and excipient combinations. It shows the over-additive effect of using two excipients together and addresses how excipients’ viscosity-reducing ability depends on pH. The results show the effect of protein viscosity on …

WHITEPAPER - Protecting Workers and the Environment: Facilities and Processes Key to Safely Making Highly Potent Drug Products

WHITEPAPER - Protecting Workers and the Environment: Facilities and Processes Key to Safely Making Highly Potent Drug Products

Highly potent APIs (HPAPI) are rapidly growing in the pharmaceutical industry. Manufacturing solid oral dosage forms (SOD) containing HPAPIs requires specific knowledge, skills, and precision without compromising environmental or worker safety.

Enteris BioPharma’s HPAPI manufacturing facility was custom-built with comprehensive …

WHITE PAPER - Nanoparticles in Drug Delivery & Photothermal Therapies

WHITE PAPER - Nanoparticles in Drug Delivery & Photothermal Therapies

Nanoparticles offer multi-functional capabilities that include the ability to be tracked within the body, deliver a specific compound at a controlled rate, target a particular location, and remotely kill cells once in place due to which their use as drug …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

July 13 – Bioavailability
July 20 – Excipients